THE GENERAL HOSPITAL CORPORATION CLINICAL TRIAL AGREEMENT (Investigator- Initiated) This Clinical Trial Agreement ("Agreement") is made as of the 28 day of September, 2009 ("Effective Date") between CytoDyn, Inc., a publicly traded corporation...Clinical Trial Agreement • September 29th, 2009 • Cytodyn Inc • Pharmaceutical preparations • Massachusetts
Standard Clinical Trial Agreement This Clinical Trial Agreement (“Agreement”), dated as of [xx/xx-xxxx] (“Effective Date”) is made by and between; Institution: (hereinafter called “Institution”) Represented by (hereinafter called ”Principal...Clinical Trial Agreement • November 18th, 2021
The Institution and Sponsor are hereinafter each individually referred to as a “Party” and collectively referred to as the “Parties”.
CLINICAL TRIAL AGREEMENT FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY SPONSORED RESEARCH IN NHS HOSPITALSClinical Trial Agreement • September 14th, 2012 • England and Wales
WHEREAS the Sponsor is a pharmaceutical company involved in the research, development, manufacture and sale of medicines for use in humans
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • November 7th, 2023
This agreement (hereinafter referred to as the "Agreement") is concluded on the date of its signing by the last party, as specified on the signature page, between:
CLINICAL TRIAL AGREEMENT – NON-COMMERCIAL RETROSPECTIVE STUDY NON ZOL SPONSOREDClinical Trial Agreement • January 21st, 2021
This Agreement may only be used as a model for a non-interventional retrospective study in which the past is studied on the basis of information that is already available at the start of the study.
Clinical Trial Agreement smlouva o klinickém hodnoceníClinical Trial Agreement • November 1st, 2017
The Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení (“Smlouva”) je uzavírána mezi následujícími stranami:
CLINICAL TRIAL AGREEMENT FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY SPONSORED RESEARCH IN GENERAL PRACTICEClinical Trial Agreement • December 16th, 2013 • England and Wales
WHEREAS the Sponsor is a pharmaceutical company involved in the research, development, manufacture and sale of medicines for use in humans
Standard Clinical Trial AgreementClinical Trial Agreement • August 30th, 2019
WHEREAS this Agreement shall be used when entering into agreements between Sponsor (defined in Appendix A) and a public institution in Denmark, represented by the Principal Investigator (defined in Appendix A);
ContractClinical Trial Agreement • December 12th, 2019
CLINICAL TRIAL AGREEMENT(Institution/Principal Investigator)This Clinical Trial Agreement (the “Agreement”) is by and between PAREXEL International Czech Republic s.r.o., with Company No: 27160360,Tax ID No: CZ27160360,represented pursuant to the Power of Attorney dated 7.December 2010 by xxx (hereinafter referred to as „CRO“) a company organized and existing under the laws of Czech Republic with its with principal offices located in the Czech Republic at Sokolovská 651/136a, 186 00 Prague 8, Czech Republic acting on behalf of Janssen- Cilag International NV Turnhoutseweg 30, 2340 Beerse, Belgium (hereinafter referred to as “Sponsor”) and in CRO’s own name and Fakultní nemocnice Brno (“Institution”) with registered offices located at Jihlavská 20, 625 00 Brno, Czech Republic, Iden.number:65269705 Tax Iden.number:CZ 65269705Represented by xxxx, director andxxxx (“Principal Investigator”), affiliated with Institution, located at Fakultní nemocnice Brno, Jihlavská 20, 625 00 Brno, Czech R
Clinical Trial AgreementClinical Trial Agreement • December 6th, 2019
The Institution and Sponsor are hereinafter each individually referred to as a “Party” and collectively referred to as the “Parties”.
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • January 4th, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • Pennsylvania
This Clinical Trial Agreement (“Agreement”) is entered into as of March 14, 2014 (“Effective Date”) by and between EASTERN COOPERATIVE ONCOLOGY GROUP, an organization with its executive office at 1818 Market St., Suite 1100, Philadelphia, PA 19103-3602, and its principal place of business at ECOG Coordinating Center, Frontier Science, 900 Commonwealth Avenue, Boston, MA 02215 (“Group”) and Syndax Pharmaceuticals, Inc., a Delaware corporation, with its principal office and place of business located at 400 Totten Pond Road, Suite 140, Waltham, Massachusetts 02451 (“Company”).
ContractClinical Trial Agreement • September 19th, 2022
ContractClinical Trial Agreement • September 13th, 2017
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ The Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení (“Smlouva”) je uzavírána mezi následujícími stranami: Nemocnice Rudolfa a Stefanie Benešov, a.s., nemocnice Středočeského kraje, having a place of business at Máchova 400, Zip code 256 01 Benešov, Czech Republic, Identification number: 27253236, Tax identification number CZ27253236, registered in the Commercial Register of the City Court in Prague unfer the Section B, number: 9996, represented by MUDr. Roman Mrva, Director (the “Institution”), and Nemocnice Rudolfa a Stefanie Benešov, a.s., nemocnice Středočeského kraje, se sídlem Máchova 400, 256 01 Benešov, Česká republika, Identifikační číslo 27253236, Daňové identifikační číslo: CZ27253236, zapsaná v obchodním rejstříku vedeném u Městského soudu v Praze, oddíl B, vložka 9996, zastoupená MUDr. Romanem Mrvou, ředitelem (“Zdravotnické zařízení”), a , having aaddress at(the “
ContractClinical Trial Agreement • August 5th, 2019
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ The Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení („Smlouva“) je uzavírána mezi následujícími stranami: • Fakultní nemocnice u sv. Anny v Brně, having a place of business at Pekařská 664/53, 656 91 Brno, Czech Republic, Identification number: 00159816, Tax identification number: CZ00159816, represented by Ing. Vlastimil Vajdák, Director (the “Institution”), and • Fakultní nemocnice u sv. Anny v Brně, se sídlem Pekařská 664/53, 656 91 Brno, Česká republika, Identifikační číslo: 00159816, Daňové identifikační číslo: CZ00159816, zastoupená Ing. Vlastimilem Vajdákem, ředitelem („Zdravotnické zařízení“), a • , having an address at, date of birth: (the “Investigator”); and • , s adresou, datum narození: („Zkoušející“); a • IQVIA RDS Czech Republic s.r.o., having a place of business at Pernerova 691/42, 186 00 Praha 8 - Karlín, Czech Republic, Identification number: 247 68 651, Tax ident
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • October 8th, 2020
the person of its special attorney Dr. Simona Vannini which is authorised to carry out the Study in the name and on behalf of Sponsor
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • December 21st, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
This Agreement is entered into as of September 11, 2011 by and between HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LIMITED, a company duly incorporated under the laws of Israel, of P.O. Box 12000, Jerusalem 91120, (hereinafter: “Hadasit” or the “Institution”) and Dr. Daniel Schurr and Dr. Miriam Kidron (the ”Investigator”) on one hand and Oramed Ltd., a corporation organized under the laws of the state of Delaware, with its registered office located at 2/5 Hi-Tech Park Givat-Ram P.O. Box 39098, Jerusalem 91390, (hereinafter: “Sponsor”), on the other hand.
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • April 18th, 2022 • New York
This Agreement is entered into on ______________ by and between (sponsor name) ______________, a _______________ established under the laws of ________________, with offices located at ______________________ and the University of Rochester (“Institution”), a not-for-profit educational institution established under the laws of New York State, with business offices located at 500 Joseph C. Wilson Blvd, RC Box 270140, Rochester, NY 14627-0001.
ContractClinical Trial Agreement • December 14th, 2016
Clinical Trial Agreement The Clinical Trial Agreement (“Agreement”) is made by and between: Revmatologický ústav, having a place of business at Na Slupi 450/4, Praha 2 – Nové Město, 128 00 Praha 28, Czech Republic, Identification Number: 00023728, Tax Identification Number: CZ00023728, represented by prof. MUDr. Karel Pavelka, DrSc., Director (the “Institution”), and Quintiles Czech Republic, s.r.o., having a place of business at Praha 5, Jinonice, Radlická 714/113a, zip code 158 00 Prague, Czech Republic, Identification number: 247 68 651, Tax identification number: CZ247 68 651, represented by Mr. Alasdair MacDonald, Managing Director (“Quintiles”), and Archigen Biotech Limited, having a place of business at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambrigde CB2 0AA, United Kingdom, Identification number: 08997356, Tax identification number: GB193046016[insert number], represented by Hyunhwa Youn, Senior Manager, Clinical Development (“Sponsor”) Each a “Party” a
ContractClinical Trial Agreement • October 8th, 2021
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ This Clinical Trial Agreement (“Agreement”), effective as of the date of last signature and upon the publication in the Register of Contracts pursuant to Act nº 340/2015 Coll, (“Effective Date”) is entered into between Regeneron Pharmaceuticals, Inc., having an address at 777 Old Saw Mill River Road, Tarrytown, NY 10591 United States, Company ID No.: 1226128 represented by (“Sponsor”) and Všeobecná fakultní nemocnice v Praze, having an address at U Nemocnice 499/2, 128 08, Czech Republic, ID NO 00064165 represented by(“Institution”). Tato smlouva o klinickém hodnocení („smlouva“),nabývá účinnosti dnem posledního podpisu a po uveřejnění v Registru smluv, dle zákona č. 340/2015 Sb., se uzavírá mezi společností Regeneron Pharmaceuticals, Inc. se sídlem na adrese 777 Old Saw Mill River Road, Tarrytown, NY 10591, Spojené státy americké, IČO: 1226128 zastoupena („zadavatel“) a Všeobecnou fakultní nemocnicí v Praze, se sídlem na adrese U
IND SPONSOR: InCHOIR CLINICAL TRIAL AGREEMENT BETWEEN THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (“NHLBI”) AND Mesoblast, Inc. Protocol # CTSNLVAD02Clinical Trial Agreement • November 2nd, 2015 • Mesoblast LTD • Biological products, (no disgnostic substances) • District of Columbia
This Clinical Trial Agreement (the “Agreement”), effective as of July 28th, 2014 (the “Effective Date”) is made by and between the National Heart, Lung, and Blood Institute (“NHLBI”), an institute of the National Institutes of Health (“NIH”), which is part of the United States Government Department of Health and Human Services (HHS), and Mesoblast, Inc. (“Company”), located at 505 Fifth Ave., 3rd Floor, New York, NY 10017 (individually referred to as the “Party” and collectively referred to as the “Parties”) for a Clinical Trial designated as Protocol # CTSNLVAD02 entitled “Safety and Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients.”
CLINICAL TRIAL AGREEMENT BETWEEN THE PENNSYLVANIA STATE UNIVERSITY AND THE MILTON S. HERSHEY MEDICAL CENTER ANDClinical Trial Agreement • April 23rd, 2021 • Pennsylvania
This Clinical Trial Agreement (hereinafter referred to as "Agreement") is entered into by and between The Pennsylvania State University [if applicable -and The Milton S. Hershey Medical Center, located at 500 UNIVERSITY Drive, Hershey, PA 17033] located at ________________________________(collectively "UNIVERSITY") and ___________________________, located at ________________________________(“SPONSOR”). Collectively the SPONSOR and UNIVERSITY may be referred to as “the Parties,” or individually as “a Party.”
This CLINICAL TRIAL AGREEMENTClinical Trial Agreement • January 2nd, 2018
(the “Agreement”) is effective November 22, 2017 (the “Effective Date”), by and between Krajská zdravotní, a.s. located at Sociální péče 3316/21A, 401 13 Ústí nad Labem, Czech Republic, represented by Ing. Petr Fiala, the executive director, duly registred in the Commercial Register maintained by the Regional Court in Ústí nad Labem, Section B, Entry 1550 (the “Institution”), Pharmaceutical Research Associates CZ, s.r.o., located at Praha 7, Jankovcova 1569/2c, Post Code (PSČ): 170 00, Czech Republic, IČ (company ID number): 27636852, the limited liability company duly registered in the Commercial Register of the Czech Republic maintained by the Municipal Court in Prague, Section C, Entry 120574, represented by MUDr. Andrea Klč, Proxy (“PRA”), an affiliate of Pharmaceutical Research Associates, Inc., located at 4130 Lake Avenue, Suite 400, Raleigh, NC 27612, USA (“PRA USA”), acting as an independent contractor for Gan & Lee Pharmaceuticals USA Corporation located at 1170 US Highway 22
CLINICAL TRIAL AGREEMENT BETWEEN AND EMORY UNIVERSITYClinical Trial Agreement • March 22nd, 2022 • Georgia
THIS Agreement, entered into by and between Emory University, a Georgia non-profit corporation with offices at 1599 Clifton Road, NE, Mailstop 1599/001/1BA, Atlanta, Georgia 30322 (“University”) and _______________________________, a corporation with its principal place of business at ________________, hereinafter referred to as “Sponsor” is for the purpose as hereinafter set forth.
ContractClinical Trial Agreement • January 9th, 2019
CLINICAL TRIAL AGREEMENT This CLINICAL TRIAL AGREEMENT (the“Agreement”) is effective on December 14, 2018 (the “Effective Date”), by and between Krajská zdravotní, a.s. located at Sociální péče 3316/21A, 401 13 Ústí nad Labem, Czech Republic, represented by Ing. Petr Fiala, the executive director, duly registred in the Commercial Register maintained by the Regional Court in Ústí nad Labem, Section B, Entry 1550 (the “Institution”), Pharmaceutical Research Associates CZ, s.r.o., located at Praha 7, Jankovcova 1569/2c, Post Code (PSČ): 170 00, Czech Republic, IČ (company ID number): 27636852, the limited liability company duly registered in the Commercial Register of the Czech Republic maintained by the Municipal Court in Prague,Section C, Entry 120574, represented(“PRA”), an affiliate of Pharmaceutical Research Associates (UK) Ltd., located at 500 Oak Way, Green Park, Reading, Berkshire RG2 6 AD, United Kingdom and with registred address at Cannon Place, 78 Cannon Street, London, EC4N 6
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • April 16th, 2020 • New York
{MONTH}, {YEAR} (the “Effective Date”) by and between THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK a nonprofit, educational corporation organized and existing under the laws of the State of New York, with an office located at Office of Sponsored Programs, Stony Brook, NY 11794-3362 at Stony Brook University (“Institution”) and {COMPANY NAME}, a corporation having its principal place of business at {COMPANY ADDRESS}(“Sponsor”). Sponsor and Institution are herein referred to
ContractClinical Trial Agreement • March 14th, 2022
CLINICAL TRIAL AGREEMENT - TRIPARTITE SMLOUVA O PROVEDENÍ KLINICKÉHO HODNOCENÍ – TROJSTRANNÁ This Agreement (“Agreement ”) is valid when signed by all parties, and it is effective as of the date of publication in register of contracts under Act No. 340/2015 Coll., on the Contract Registry (hereinafter the “Effective Date” subject to compliance with the requirement to publish the redacted version of the Agreement in accordance with Section 13 (Registration of the Agreement), by and between TATO SMLOUVA (dále jen „smlouva“) je platná po podpisu všemi stranami a nabývá účinnosti k datu uveřejnění v registru smluv ve smyslu zákona č. 340/2015 Sb., o registru smluv (dále jen „den účinnosti“), podle požadavku na zveřejnění upravené verze smlouvy v souladu s článkem 13 (Registrace smlouvy), mezi společností ICON Clinical Research Limited with a place of business at South County Business Park, Leopardstown, Dublin 18, Ireland, VAT number IE 8201978R, represented by XXXXXXXXXX, XXXXXXXXXX (
Clinical Trial AgreementClinical Trial Agreement • October 22nd, 2019 • BriaCell Therapeutics Corp. • Pharmaceutical preparations
This Clinical Trial Agreement (“Agreement”) is made on 1/26/2018 (the “Effective Date”) by and between St. Joseph Heritage Healthcare (“Institution”), a California nonprofit public benefit corporation with an address at 200 W. Center Street Promenade, Suite 800, Anaheim, California 92805; Jarrod Holmes, M.D. (“Principal Investigator”), a contractor of Institution with an office located at 3555 Round Barn Circle, Santa Rosa, CA 95403, and Cancer Insight, LLC (“CRO”), a limited liability company having its principal place of business at 110 E. Houston Street, San Antonio, TX 78205. CRO, Institution and Principal Investigator are herein referred to collectively as “Parties.” Individually, each of CRO and Institution is a “Party.”
CLINICAL TRIAL AGREEMENT Agreement made this 15th day of November, 1999 ("Effective Date") between The General Hospital Corporation, a not-for-profit corporation doing business as Massachusetts General Hospital, having a principal place of business at...Clinical Trial Agreement • April 14th, 2000 • Laser Photonics Inc • Miscellaneous electrical machinery, equipment & supplies • Massachusetts
Clinical Trial AgreementClinical Trial Agreement • November 10th, 2016 • Creative Medical Technology Holdings, Inc. • Biological products, (no disgnostic substances) • California
This Clinical Trial Agreement (“Agreement”) is made as of this 19th day of September, 2016 (“Effective Date”) by and between Creative Medical Technologies, Inc. with a place of business at 2017 W. Peoria Avenue, Phoenix, AZ, 85029 (“CMT”) and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, a non-profit biomedical research and education institute located at 1124 W. Carson Street, Building N-14, Torrance, CA 90502 (“Institution”).
This Agreement is between [name of Entity] and [name of IC] for the clinical development ofClinical Trial Agreement • July 9th, 2015 • District of Columbia
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • July 26th, 2017
Chiltern International s.r.o., Business Centrum Zalesi Building A2, Pod Visnovkou 1661/31, 140 00 Praha 4 – Krc, Czech Republic, registered in the Commercial Register maintained by the Municipal Court in Prague, section C., Insert: 130938, company identification number: 281 78 777, represented by , Executive manager (hereinafter referred to as “Chiltern”); and
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • January 24th, 2019
Each of the Sponsor, the Institution and the Principal Investigator may be referred to herein individually as a "Party", and collectively as the "Parties".
ContractClinical Trial Agreement • October 15th, 2019
CLINICAL TRIAL AGREEMENT The Clinical Trial Agreement (“Agreement”) is made by and between: • Nemocnice Na Bulovce, having a place of business at Budínova 67/2, 180 81 Praha 8, Czech Republic, Identification number: 00064211, Tax identification number: CZ00064211, represented(the “Institution”), and • IQVIA RDS Czech Republic s.r.o., having a place of business at Pernerova 691/42, 186 00 Praha 8 - Karlín, Czech Republic, Identification number: 24768651, Tax identification number: CZ24768651, represented by Ing. Martin Šlégl, Executive Director (“IQVIA”), and • Genmab A/S, having a place of business at Kalvebod Brygge 43, 1560 Copenhagen V, Denmark, Identification number: CVR no. 2102 3884, represented by Michael Karl Bauer (“Sponsor”) Each a “Party” and together the “Parties”. Protocol Number: GCT1015-05A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® - TF -ADC) inProtocol Title: Combination with Other Agents in Subjects withRecurrent or Stage IVB Cervical Cancer Protocol Dat
SEATTLE GENETICSClinical Trial Agreement • October 17th, 2018
This Clinical Trial Agreement (the “Agreement”) is made as of the day the last party to subscribe below (the “Effective Date”) by and between
ContractClinical Trial Agreement • September 9th, 2019
CLINICAL TRIAL AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ The Clinical Trial Agreement (“Agreement”) is made by and between: Tato smlouva o klinickém hodnocení („Smlouva“) je uzavírána mezi následujícími stranami: Thomayerova nemocnice, located at Vídeňská 800, 140 59 Praha 4 – Krč, Czech Republic, Identification number: 00064190, Tax identification number: CZ00064190, state contributory organization established by the Ministry of Health of the Czech Republic, full text of foundation deed No. MZDR 17268-IV/2012, registered in Companies Registry by Municipal Court in Prague, Section PR, inlet 1043 represented by doc. MUDr. Zdeněk Beneš CSc., Director (the “Institution”); and Thomayerova nemocnice, se sídlem Vídeňská 800 140 59 Praha 4 - Krč, Českárepublika, Identifikační číslo: 000 64 190, Daňové identifikační číslo: CZ00064190, státní příspěvková organizace zřízená Ministerstvem zdravotnictví ČR, úplné znění zřizovací listiny č.j. MZDR 17268- IV/2012, zapsaná v obchodním rejstří
